Educational content only — this is not medical advice. Nothing here is a recommendation to buy, obtain, or use Larazotide Acetate. Talk to a licensed clinician before making health decisions.
What it is
Larazotide is a synthetic peptide derived from a Vibrio cholerae enterotoxin sequence. It is designed to reduce intestinal permeability by modulating tight junctions, with the goal of preventing gluten-induced immune activation in people with celiac disease. It is intended as an adjunct to a gluten-free diet, not a replacement.
What the evidence shows
Phase 2 and 3 RCTs have produced mixed results. Early trials suggested reduced gluten-induced symptoms and immune markers, but later Phase 3 trials did not meet their primary endpoints consistently. A 2023 meta-analysis concluded that larazotide shows some symptom benefit but robust, reproducible efficacy has not been established. Development continues, and regulatory approval has not been granted.
Risks & unknowns
Larazotide has generally been well tolerated, with headache, upper respiratory symptoms, and gastrointestinal upset reported more commonly than placebo. Because it targets intestinal permeability, its effects on nutrient absorption and drug bioavailability are theoretical considerations.
Legal / regulatory status
Larazotide acetate is not FDA-approved. It is investigational and has been studied only in clinical trials. It is not a substitute for a gluten-free diet in celiac disease.